| 1.36 -0.01 (-0.73%) | 12-05 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.97 | 1-year : | 2.33 |
| Resists | First : | 1.69 | Second : | 2 |
| Pivot price | 1.33  |
|||
| Supports | First : | 1.2 | Second : | 0.99 |
| MAs | MA(5) : | 1.43 |
MA(20) : | 1.32  |
| MA(100) : | 2.17 |
MA(250) : | 2.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.9 |
D(3) : | 38.6 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 9.53 | Low : | 0.91 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTPI ] has closed below upper band by 43.1%. Bollinger Bands are 63.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.63 - 1.64 | 1.64 - 1.65 |
| Low: | 1.25 - 1.26 | 1.26 - 1.27 |
| Close: | 1.35 - 1.36 | 1.36 - 1.37 |
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Tue, 05 Dec 2023
Petros Pharmaceuticals Inc (PTPI) Stock Has Gained 22.48% This Week: Buy, Hold, or Sell? - InvestorsObserver
Mon, 04 Dec 2023
Petros Pharmaceuticals Inc (PTPI) Up 4.76% in Premarket Trading - InvestorsObserver
Fri, 01 Dec 2023
Should You Buy Petros Pharmaceuticals Inc (PTPI) Stock Friday Morning? - InvestorsObserver
Thu, 30 Nov 2023
How Will the Market React to Petros Pharmaceuticals Inc (PTPI) Stock Getting a Bullish Rating - InvestorsObserver
Mon, 30 Oct 2023
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent ... - Yahoo Finance
Fri, 29 Sep 2023
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor - AlphaStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 32.6 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 61 (K) |
| EPS | -6.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | -181.9 % |
| Operating Margin | -116.6 % |
| Return on Assets (ttm) | -16.1 % |
| Return on Equity (ttm) | -92 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.17 |
| EBITDA (p.s.) | -2.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | 0.41 |
| Price to Sales | 0.42 |
| Price to Cash Flow | -0.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|